An observational study in Heart Transplant Rejection and Microvascular Resistance, sponsored by Hospital Miguel Servet. Recruiting at 2 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-21.
Sponsored by Hospital Miguel Servet · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Acute allograft rejection (AAR) is an important cause of morbi-mortality in heart transplant (HT) patients, particularly during the first year. Endomyocardial biopsy (EMB) is the "gold standard" to guide post- heart transplantation treatment. However, it is associated with complications that can be potentially serious. The index of microvascular resistance (IMR) is a specific physiological parameter used to assess microvascular function. Invasive coronary assessment has been shown to be both feasible and safe. Detection of coronary microvascular dysfunction (MCD) by IMR may help to identify high risk HT patients. In fact, an increased IMR measured early after HT has been associated with AAR, higher all-cause mortality and adverse cardiac events. A high IMR value early after HT may identify patients at higher risk who require increased surveillance or adjustments in immunosuppressive therapy. Conversely, a low IMR value may support reducing the number of EMBs. Our aim is to evaluate IMR in heart transplant patients within the first year. Changes in management after knowing IMR values and prognostic implications of IMR in a long term follow up will also be assessed.
The IMR-HT study is a multicenter, prospective observational study that will include post-HT stable patients undergoing coronary physiological assessment in the first three months and one year.
Assessment of IMR, coronary flow reserve (CFR) and fractional flow reserve (FFR) will be performed using the standard thermodilution technique. The left anterior descending coronary artery will be evaluated in all patients. Circumflex or right coronary artery could be additionally evaluated at operator's discretion. An intracoronary pressure and temperature sensor-tipped guidewire (Pressure Wire TM X guide- wire 0.014', Abbott, IL, USA) will be used to perform the measurements. The tip pressure sensor will be advanced into the mid-to-distal portion of the evaluated vessel. Baseline aortic pressure (Pa) and distal intracoronary pressure (Pd) will be obtained to calculate the resting index Pd/Pa. To measure the mean transit time (Tmn) under basal conditions, intracoronary administration of 3 mL of room-temperature saline will be manually injected three times in succession (3 mL/s). Then maximal hyperemia will be induced using adenosine iv (140 to 180 mg/kg/min) and three additional intracoronary room temperature saline boluses of 3 ml will be administered to determine the mean transit time at hyperemia (Tmnh). Finally, fractional flow reserve (FFR), coronary flow reserve (CFR) and IMR will be calculated using the software Coroventis Coroflow (Coroventis Abbott, Uppsala, Sweden).
Changes in HT patient management (number of EMBs, immunosuppressive therapy modifications) after knowing IMR values will also be assessed.
Based on previously published clinical data on IMR in heart transplant patients, a post-HT management algorithm is proposed:
Of note, given the observational characteristics of the study, clinical management decisions will be made at the discretion of the treating physician, taking into account the patient's clinical condition and other complementary tests.
Both groups (IMR\<15 vs IMR≥15) will be compared in terms of cardiac events occurrence.
Clinical conditions, laboratory findings and clinical events will be assessed at one month and one year. Follow up will be extended for up to five years. Data will be included in an online database specifically designed for the study on platform REDCap (Research Electronic Data Capture).
A number will be assigned to each patient; their identity will not be disclosed in any case. All shared information will be anonymized. The principal investigator at each center will be responsible for keeping the data anonymized.Data will be processed in accordance with the protection legislation in force (Spanish Personal Data Protection and Guarantee of Digital Rights Act 3/2018, and Regulation (EU) 2016/679).
Our aim will be to assess IMR values in heart transplant patients within one year and evaluate changes in management after knowing of IMR values. We believe it is important to move forward in AAR surveillance and reduce the number of endomyocardial biopsies. In addition to assessing their diagnostic capabilities, IMR should also be assessed based on clinical outcomes. Therefore, we are convinced the results of this trial will be very important for our HT patient population.
Hospital Miguel Servet is the lead sponsor of 25 studies on the registry; 4 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Heart trasplant patients that have signed informed consent and meet all inclusion and exclusion criteria for undergoing IMR assessment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Heart trasplant patient with an index of microvascular resistance ≥ 15 measured in the first three months in the physiological study.
Heart trasplant patient with an index of microvascular resistance\<15 measured in the first three months in the physiological study.
IMR values in the first three months and one year after heart transplant
IMR measured by the invasive thermodilution technique. IMR is defined as the distal coronary pressure divided by the inverse of the hyperemic mean transit time and is expressed in units of mmHg.s.
Time frame: One year
IMR variation between first three months after HT and one year
Comparison between the values of index of microvascular resistance (IMR) measured by bolus thermodilution technique between the first and 3rd month after HT and one year in the invasive physiological study. IMR may be expressed as mmHg·s.
Time frame: One year
Acute cellular rejection
A ≥2R degree according to the 2010 ISHLT system. Two or more focal infiltration points associated with myocyte injury in EMB. Diffuse infiltration with multi-focal myocyte injury with/without oedema, hemorrhage or vasculitis.
Time frame: One year
Cardiac allograft vasculopathy
Accelerated fibroproliferative process characterized by diffuse, concentric and longitudinal thickening of the intima of the vascular tree of the graft, affecting everything from the major epicardial arteries to the coronary microvasculature.
Time frame: Five years
Cardiovascular mortality
Caused by cardiovascular disease or unknown death
Time frame: Five years
Heart failure
Diastolic or systolic heart failure after heart transplant
Time frame: Five years
Inmunosupressive therapy
Changes in any of the inmunosuppresive agents pre-established in each center heart transplant protocol
Time frame: Five years
EMB performed in each center within the first year
The number of biopsies performed by each center, after knowing IMR baseline values.
Time frame: One year
Not enrolling at this site.
Plan to share: Yes — All collected IPD
Supporting information: Study protocol, Statistical analysis plan
Time frame: October 2024
Access criteria: All researches/physicians involved in this investigational field
Started May 2023 (actual). Primary completion is estimated for May 2028, 60 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hospital Miguel Servet